- Company
- First ASMD treatment Xenpozyme to land in Korea
- by Eo, Yun-Ho Nov 24, 2022 05:51am
- The first-ever pediatric storage disorder treatment is expected to be introduced to Korea. According to industry sources, Sanofi Genzyme’s treatment for acid sphingomyelinase deficiency (ASMD) ‘Xenpozyme (olipudase alfa)’ is undergoing processes for marketing authorization by the Ministry of Food and Drug Safety. Starting with Jap
- Company
- Shaperon applies for a patent for biomarkers,
- by Lee, Seok-Jun Nov 24, 2022 05:50am
- Shaperone announced on the 23rd that it has applied for a patent to prove the correlation between NuGel, an atopic dermatitis treatment under development, and biomarkers (biological markers). The patent is the result of analyzing the data of phase 2 patients with atopic dermatitis in Korea and confirming that biomarkers in the blood can be ef
- Company
- Chong Kun Dang CKD-701, equivalent to Lucentis' original
- by Chon, Seung-Hyun Nov 24, 2022 05:50am
- Chong Kun Dang announced on the 23rd that the results of phase 3 clinical trials of the macular degeneration treatment Lucentis biosimilar CKD-701 were published in the SCI-level international academic journal PLoS One. Chong Kun Dang conducted phase 3 clinical trials of CKD-701 in 312 patients with neovascular age-related macular degeneratio
- Company
- SK Bio "hasn't manufactured SKYCovione after first batch"
- by Kim, Jin-Gu Nov 24, 2022 05:50am
- On the 23rd, SK Bioscience publicly announced that the manufacture and supply of its self-developed COVID-19 vaccine ‘SKYCovione’ have currently been discontinued. SK Bioscience received marketing authorization for SKYCovione in Korea in July this year. In September, the company supplied an initial batch of 60 thousand doses of the 10
- Company
- Kadcyla can be prescribed after registering benefit
- by Eo, Yun-Ho Nov 23, 2022 06:04am
- According to related industries, anticancer drugs such as ADC and Antibody-drug conjugate Kadcyla and CDK4/600 inhibitor Verzenio are entering the early breast cancer area in Korea. Kadcyla was already listed on the insurance benefit list in July, and the actual prescription began. The drug, which was used for the second or more treatment of
- Company
- Imjudo is expected to be introduced in Korea
- by Eo, Yun-Ho Nov 23, 2022 06:03am
- Another immuno-cancer drug with CTLA-4 inhibitory mechanism is expected to be introduced in Korea. According to related industries, AstraZeneca Korea has submitted an application for domestic permission for CTLA-4 inhibitor Imjudo, a partner in combination therapy for PD-L1 inhibitor Impinzi. The combination therapy of Impinzi and Imjudo was
- Company
- Attention focused on whether Luxturna will be reimb in Korea
- by Eo, Yun-Ho Nov 22, 2022 06:04am
- Discussions on expanding coverage of the one-shot gene therapy ‘Luxturna’ is not making much progress. Therefore, the industry’s eyes are on whether Novartis Korea’s Inherited Retinal Dystrophy (IRD) treatment Luxturna (voretigene neparvovec) will be presented as an agenda for deliberation by the Health Insurance Review and Assessmen
- Company
- GSK Duodart can be prescribed at general hospitals
- by Eo, Yun-Ho Nov 22, 2022 06:04am
- Duodart, a prostate hypertrophy compound, has settled in general hospitals. According to related industries, GSK Korea's Duodart recently passed DC of Big 5 General Hospitals such as Samsung Medical Center, Seoul National University Hospital, Asan Medical Center, and Sinchon Severance Hospital. This drug has been applied to insurance benefits
- Company
- Evrysdi can be prescribed with non-reimbursement
- by Eo, Yun-Ho Nov 21, 2022 05:56am
- Evrysdi, an eating spinal muscular atrophy treatment, can be prescribed at hospitals and is still non-reimbursement. According to related industries, Roche Korea's Spinal Muscular Atrophy treatment passed through D.C. at medical institutions such as Severance Hospital, Seoul National University Hospital, Yangsan Pusan National University Hosp
- Company
- Dong-AST ended the clinical trial of Stelara biosimilar
- by Chon, Seung-Hyun Nov 21, 2022 05:56am
- Dong-AST announced on the 17th that the global phase 3 clinical trial of Stella biosimilar DMB-3115 has ended. Phase 3 of global clinical trials of DMB-3115 was conducted for 52 weeks in a total of 605 patients in 9 countries, including Poland, Estonia, and Latvia, starting in the United States in 2021. Phase 3 of this global clinical trial w
